

**In the claims:**

Please cancel claims 1-10 and add new claims 11-13 as follows:

Claims 1-10 (Canceled)

11. (New) A method of treating acute or chronic rejection in a xenograft transplantation patient, which comprises administering to a patient receiving a xenograft a therapeutically effective amount of a leflunomide product, wherein said product is N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxanilide or N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide.

12. (New) The method of claim 11, wherein the xenograft is skin, heart, kidney, liver, bone, pancreas, or blood.

13. (New) The method of claim 11, wherein the leflunomide product is administered at 10 mg/kg of body weight per day.